Kadcyla not so NICE
April 28, 2014
The UK National Institute for
Health and Care Excellence (NICE)
in its evaluation of trastuzumab
emtansine (Kadcyla by Roche) as a
treatment option for people with
HER2-positive breast cancer, is
challenging the cost-effectiveness
of the product based on “the price
the NHS is being asked to pay.”
The breast cancer treatment can
cost more than £90,000 per patient
and is presently funded through the
special Cancer Drugs Fund but is
unlikely at this stage to be listed on
the NHS, according to NICE.
Kadcyla was registered in
Australia by the Therapeutic Goods
Administration (TGA) on 03 Sep
2013 “as a single agent, indicated
for the treatment of patients with
HER2 positive metastatic (Stage
IV) breast cancer who previously
received trastuzumab and a taxane,
separately or in combination,” the
TGA said.
Other conditions also apply to its
use but the product is not listed on
the Australian PBS.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Apr 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Apr 14
